Evolving CLL treatments: creating choices and igniting discussions
Deborah Henderson, chronic lymphocytic leukemia (CLL) patient advocate and journalist, is joined by Michael Hallek, MD, PhD from the University of Cologne, Cologne, Germany to talk about his session on the ‘Evolution of Treatment in Relapsed/Refractory CLL’ at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY. During this popular session, Prof. Hallek discussed how the novel combination of therapies has allowed long-term remission to be an achievable treatment aim. It was apparent during the session though, that there is a lack of consensus among physicians regarding what the best treatment options are and what the treatments goals are for physicians. As an experienced patient advocate, Deborah moves the discussion towards medical inequalities that exist in CLL treatment.
Видео Evolving CLL treatments: creating choices and igniting discussions канала VJHemOnc – Video Journal of Hematology & HemOnc
Видео Evolving CLL treatments: creating choices and igniting discussions канала VJHemOnc – Video Journal of Hematology & HemOnc
Показать
Комментарии отсутствуют
Информация о видео
1 июня 2017 г. 15:19:22
00:08:08
Другие видео канала
Pros and cons of autologous and allogeneic CAR-TsPOLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCLIs CAR-T therapy going to replace stem cell transplantation in myeloma in the next five years?Results from a Phase II trial of pirtobrutinib, venetoclax, and obinutuzumab in CLLChoosing between isatuximab & daratumumab in multiple myelomaDefining precursor states in multiple myelomaThe role of belantamab mafodotin in myeloma treatment and managing the associated ocular toxicitiesThe exciting future of bispecific antibodiesThe promise of mutant CALR antibodies for the treatment of MPNsIPSS-R vs IPSS-M for MDSVenetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline CLL: updates from GAIA/CLL13CAR T-cell therapy; guidelines for nursesMRD Focus: why measurable residual disease testing is the futureUpdates from a Phase I study evaluating dendritic cell therapy, cryosurgery & pembrolizumab in NHLSURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemiaMRD negativity in ALLPalliative treatment of waldenström’s macroglobulinemiaSide effects of CAR T-cell therapy and their managementInsights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLLThe demographics of patients with beta-thalassemiaGENESIS: Motixafortide prior to HCT in patients with MM